Abstracts tagged "Pegloticase"

Abstract Number: 0680 • ACR Convergence 2021
Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions
N Lawrence Edwards¹, Brian LaMoreaux², Joseph Vitriol³ and Adam Magerman³, ¹University of Florida College of Medicine, Gainesville, FL, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics, Deerfield, IL
Background/Purpose: Pegloticase is FDA-approved for uncontrolled gout and effectively lowers uric acid levels by conversion of circulating uric acid to allantoin, which is readily removed…
Abstract Number: 1529 • ACR Convergence 2021
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Huifeng Yun¹, Brian LaMoreaux², Lang Chen³, Stephanie Ledbetter³, Megan Francis-Sedlak², Kenneth Saag³, Ted Mikuls⁴ and Jeffrey Curtis⁵, ¹University of Alabama Birmingham, Birmingham, AL, ²Horizon Therapeutics plc, Deerfield, IL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
Abstract Number: 1214 • 2019 ACR/ARP Annual Meeting
The Effects of Pegloticase on Mean Arterial Blood Pressure: An Age Modulated Relationship?
Saadia Waheed¹, Hafiz Muhammad Zubair ², aamer ubaid ³, farishta waheed ³ and Linda Burns ⁴, ¹Sisters of Charity Hospital, Buffalo, NY, ²Sisters of Charity Hospital, buffalo, ³Khyber Teaching Hospital, Peshawar, Pakistan, ⁴Buffalo Rheumatology and Medicine, Buffalo
Background/Purpose: Multiple studies indicate hyperuricemia as an independent risk factor for hypertension. However, the association is found to be age-dependent and weakens as the patient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].